Sarepta Stock Decline

Order byBest matchMost fresh

Sarepta stock extends decline

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an unrelated drug.

· 1d · on MSN

Sarepta stock extends decline as company declines FDA call to withdraw drug

· 7h

Sarepta Shares Slide Again as Drugmaker Bows to FDA Pressure to Pause Gene Therapy

· 6h

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Shares of drugmaker Sarepta Therapeutics continued to fall Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of its gene therapy following s...

· 8h

Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.

STAT · 12h

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Hoodline2d

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Opendoor Technologies shares bounce again after turbulent trading

Opendoor Technologies shares are up nearly 12% as traders continue to buy the meme stock after [Monday's extreme volatility](

GEN - Genetic Engineering and Biotechnology News2d

StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after announcing of a restructuring that entailed cutting about 500 jobs,

Forbes4y

Sarepta, Vertex, Neurocrine: There’s Deep Value In These ... - Forbes

Sarepta Therapeutics, a company that develops RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, has seen its stock decline by 54% year-to-date. The decline is due to ...